Product
SENS-501
1 clinical trial
9 indications
Indication
OTOFT Gene MutationIndication
DFNB9Indication
Congenital DeafnessIndication
Hearing DisordersIndication
Ear DiseasesIndication
Otorhinolaryngologic DiseasesIndication
Hearing LossIndication
Hearing impairmentIndication
SensorineuralClinical trial
A Phase I/II, Open-ended, Adaptative, Open Label Dose Escalation and Expansion Clinical Trial to Evaluate the Efficacy and Safety of Unilateral Intracochlear Injection of SENS-501 Using an Injection System in Children With Severe to Profound Hearing Loss Due to Otoferlin Gene MutationsStatus: Not yet recruiting, Estimated PCD: 2027-04-01